Bristol-Myers Squibb (BMY) Tops Q4 EPS by 10c, offers guidance
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $63.06 +0.35%
EPS Growth %: +5.5%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +5.5%
Financial Fact:
Net Sales: 4.92B
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.70, $0.10 better than the analyst estimate of $1.60. Revenue for the quarter came in at $11.48 billion versus the consensus estimate of $11.22 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2024 EPS of $7.10-$7.40, versus the consensus of $7.39.
Revenues Increasing by Low Single-Digits.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb Co. (BMY) PT Raised to $82 at Piper Sandler
- Redburn upgrades Southwest, stays bullish on Delta and United
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
